Efficacy of therapeutic drug monitoring of mTOR inhibitor (Everolimus) in patients with renal cell carcinoma
Not Applicable
- Conditions
- Metastatic renal cell carcinoma
- Registration Number
- JPRN-UMIN000011893
- Lead Sponsor
- Osaka General Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients in contraindication 2. Patients with hepatic function disorder 3. Patients diagnosed as interstitial pneumonia 4. Patients who have already treated with Everolimus 5. Patients who are judged as inadequate by doctor in attendance
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method